Submitting.
She was then instrumental in the company integration and broader CLS services strategy in her vice-president role.
Clare Doris and Clare Wareing of Cumulus Oncology, which is based in Edinburgh. Picture: Stewart Attwood
Clare Wareing, chief executive and co-founder of Cumulus Oncology, said: “In her role at Aquila, Clare was instrumental in transforming the company from a start-up to a successful specialist service provider, while leading collaborations supporting value creation and fundraising efforts for a range of biotech companies.
“This kind of experience is a great fit for where we are at on the Cumulus journey, with our own plans to scale the business over the next few years.”
Cumulus Oncology eyes new hires and US office opening in 2021
Edinburgh-based drug discovery accelerator also seeking further venture capital backing for growth
Sign up to FREE email alerts from
businessInsider -
Subscribe
When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. OurPrivacy Noticeexplains more about how we use your data, and your rights. You can unsubscribe at any time.
Thank you for subscribingWe have more newslettersShow meSee ourprivacy notice
Drug discovery accelerator Cumulus Oncology is eyeing global alliances, venture capital partnerships and a US office opening in 2021.